Literature DB >> 32241847

A case of Epstein Barr virus-related post-transplant lymphoproliferative disorder after haploidentical allogeneic stem cell transplantation using post-transplantation cyclophosphamide.

Cindy Lynn Hickey1, Rizwan Romee2, Sarah Nikiforow2, David Dorfman3, Michael Mazzeo2, John Koreth2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32241847      PMCID： PMC7327621          DOI： 10.3324/haematol.2019.236067

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.

Authors:  Joost W J van Esser; Hubert G M Niesters; Bronno van der Holt; Ellen Meijer; Albert D M E Osterhaus; Jan Willem Gratama; Leo F Verdonck; Bob Löwenberg; Jan J Cornelissen
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

2.  Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study.

Authors:  I Esteves; C Bonfim; R Pasquini; V Funke; N F Pereira; V Rocha; Y Novis; C Arrais; V Colturato; M P de Souza; M Torres; J F Fernandes; F R Kerbauy; A A F Ribeiro; F P S Santos; N Hamerschlak
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

3.  EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era.

Authors:  C P Fox; D Burns; A N Parker; K S Peggs; C M Harvey; S Natarajan; D I Marks; B Jackson; G Chakupurakal; M Dennis; Z Lim; G Cook; B Carpenter; A R Pettitt; S Mathew; L Connelly-Smith; J A L Yin; M Viskaduraki; R Chakraverty; K Orchard; B E Shaw; J L Byrne; C Brookes; C F Craddock; S Chaganti
Journal:  Bone Marrow Transplant       Date:  2013-11-11       Impact factor: 5.483

4.  Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia.

Authors:  J Styczynski; P Reusser; H Einsele; R de la Camara; C Cordonnier; K N Ward; P Ljungman; D Engelhard
Journal:  Bone Marrow Transplant       Date:  2008-12-01       Impact factor: 5.483

5.  Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis.

Authors:  Jennifer A Kanakry; Yvette L Kasamon; Javier Bolaños-Meade; Ivan M Borrello; Robert A Brodsky; Ephraim J Fuchs; Nilanjan Ghosh; Douglas E Gladstone; Christopher D Gocke; Carol Ann Huff; Christopher G Kanakry; Leo Luznik; William Matsui; Huzefa J Mogri; Lode J Swinnen; Heather J Symons; Richard J Jones; Richard F Ambinder
Journal:  Biol Blood Marrow Transplant       Date:  2013-07-18       Impact factor: 5.742

6.  Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia.

Authors:  Jennifer Clay; Austin G Kulasekararaj; Victoria Potter; Francesco Grimaldi; Donal McLornan; Kavita Raj; Hugues de Lavallade; Michelle Kenyon; Antonio Pagliuca; Ghulam J Mufti; Judith C W Marsh
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-10       Impact factor: 5.742

7.  Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation.

Authors:  P Comoli; S Basso; M Zecca; D Pagliara; F Baldanti; M E Bernardo; W Barberi; A Moretta; M Labirio; M Paulli; M Furione; R Maccario; F Locatelli
Journal:  Am J Transplant       Date:  2007-06       Impact factor: 8.086

8.  Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.

Authors:  Anna Maria Raiola; Alida Dominietto; Carmen di Grazia; Teresa Lamparelli; Francesca Gualandi; Adalberto Ibatici; Stefania Bregante; Maria Teresa Van Lint; Riccardo Varaldo; Anna Ghiso; Marco Gobbi; Angelo Michele Carella; Alessio Signori; Federica Galaverna; Andrea Bacigalupo
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-05       Impact factor: 5.742

9.  Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT.

Authors:  Nicole Santoro; Myriam Labopin; Federica Giannotti; Gerard Ehninger; Dietger Niederwieser; Arne Brecht; Matthias Stelljes; Nicolaus Kröger; Herman Einsele; Matthias Eder; Michael Hallek; Bertram Glass; Jürgen Finke; Fabio Ciceri; Mohamad Mohty; Annalisa Ruggeri; Arnon Nagler
Journal:  J Hematol Oncol       Date:  2018-04-16       Impact factor: 17.388

10.  Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis.

Authors:  R Crocchiolo; S Bramanti; A Vai; B Sarina; R Mineri; E Casari; F Tordato; E Mauro; I Timofeeva; E Lugli; D Mavilio; C Carlo-Stella; A Santoro; L Castagna
Journal:  Transpl Infect Dis       Date:  2015-04       Impact factor: 2.228
View more
  1 in total

1.  Epstein-Barr virus-related lymphoproliferative disorders in T-cell repleted haploidentical transplantation with post-transplant cyclophosphamide.

Authors:  Vedat Uygun; Nazan Özsan; Hayriye Daloğlu; Seda Öztürkmen; Koray Yalçın; Gülsün Karasu; Akif Yeşilipek
Journal:  Int J Hematol       Date:  2021-11-26       Impact factor: 2.490
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.